Computer-Aided Selection of Potential Antihypertensive Compounds with Dual Mechanism of Action
- 24 June 2003
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (15) , 3326-3332
- https://doi.org/10.1021/jm021089h
Abstract
The prediction of biological activity spectra for substances as an approach for searching compounds with complex mechanisms of action was studied. New compounds with dual mechanisms of antihypertensive action were found by this approach. Biological activity spectra for substances were predicted on the basis of their structural formulas by the computer program PASS. Thirty molecular mechanisms of action of compounds from the MDDR 99.2 database, which cause the antihypertensive effect and can be predicted by PASS, have been identified. The analysis of predictions for compounds with 15 dual antihypertensive mechanisms of action from the MDDR 99.2 database has confirmed high accuracy of prediction. This approach was applied to databases of commercially available compounds (AsInEx and ChemBridge) and allowed us to select four substances that are potential inhibitors of angiotensin converting enzyme (ACE) and of neutral endopeptidase (NEP). At a later time, all these compounds were found to be the inhibitors of both ACE and NEP. The most potent compounds had IC50 of 10-7−10-9 M for ACE and 10-5 M for NEP. New combinations of dual mechanisms of action never before found for antihypertensive compounds were predicted.Keywords
This publication has 20 references indexed in Scilit:
- Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertensionAmerican Journal of Hypertension, 2002
- Robustness of Biological Activity Spectra Predicting by Computer Program PASS for Noncongeneric Sets of Chemical CompoundsJournal of Chemical Information and Computer Sciences, 2000
- Cgs 34043: A non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11Life Sciences, 2000
- Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjectsAmerican Journal of Hypertension, 1999
- Benzofused Macrocyclic Lactams as Triple Inhibitors of Endothelin-Converting Enzyme, Neutral Endopeptidase 24.11, and Angiotensin-Converting EnzymeJournal of Cardiovascular Pharmacology, 1998
- Design of Orally Active Dual Inhibitors of Neutral Endopeptidase and Angiotensin-Converting Enzyme with Long Duration of ActionJournal of Medicinal Chemistry, 1996
- Potent dual antagonists of endothelin and angiotensin II receptors derived from α-phenoxyphenylacetic acids (Part III)Bioorganic & Medicinal Chemistry Letters, 1995
- Inhibition of Big ET-1-Induced Pressor Response by an Orally Active Dual Inhibitor of Endothelin-Converting Enzyme and Neutral Endopeptidase 24.11Journal of Cardiovascular Pharmacology, 1995
- Cardiovascular Effects of YM-16151–4Journal of Cardiovascular Pharmacology, 1993
- Quantitative structure-activity relationships and the unnamed scienceAccounts of Chemical Research, 1993